Orris

Metformin

Reading File
Metformin is a biguanide oral antidiabetic drug, the first-line medication for type 2 diabetes. It primarily lowers blood glucose by reducing hepatic glucose production (gluconeogenesis), improving insulin sensitivity in peripheral tissues, and slowing intestinal glucose absorption. It does not cause hypoglycemia on its own and is weight-neutral or mildly weight-reducing.
Searching sources...
Finding Sources
Searching PubMed

metformin type 2 diabetes

Searching the Web

metformin mechanism of action clinical uses 2025

Reading File
Reading File
Reading File
Here is a thorough overview of metformin:

Metformin (Biguanide)

Brand names: Glucophage, Glucophage XR, Glumetza, Fortamet, Riomet

Drug Class & First-Line Status

Metformin is a biguanide and the most widely used antidiabetic medication worldwide. It is the preferred initial therapy for type 2 diabetes mellitus (T2DM) per ADA and AACE guidelines due to its efficacy, safety profile, low cost, and cardiometabolic benefits. - Goldman-Cecil Medicine, p. 983

Mechanism of Action

  1. Hepatic gluconeogenesis inhibition (primary): Metformin enters hepatocytes via organic cation transporters and inhibits mitochondrial Complex I of the electron transport chain. This raises the AMP:ATP ratio, activating AMPK (AMP-activated protein kinase), which suppresses the key enzymes of gluconeogenesis (including fructose-1,6-bisphosphatase). The result is reduced hepatic glucose output.
  2. Improved peripheral insulin sensitivity: Enhances insulin-stimulated glucose uptake in skeletal muscle, partly via AMPK-driven GLUT4 translocation.
  3. Reduced intestinal glucose absorption: Modest decrease in GI glucose uptake.
  4. No stimulation of insulin secretion - therefore it does not cause hypoglycemia as monotherapy.

Clinical Efficacy

ParameterEffect
HbA1c reduction1.0 - 1.5% (11-16 mmol/mol)
Body weightNeutral to modest weight loss
Cardiovascular outcomesReduces CV events and death in obese T2DM (UKPDS)
Hypoglycemia riskNone as monotherapy
  • Goldman-Cecil Medicine, p. 985

Dosing

Adults (immediate release):
  • Start: 500 mg BID with meals (or 850 mg once daily)
  • Titrate: increase by 500 mg/week as tolerated
  • Maximum: 2550 mg/day in divided doses
Adults (extended release):
  • Start: 500 mg once daily with evening meal
  • Maximum: 2000-2500 mg/day
Children (10-16 years):
  • Start: 500 mg BID, titrate to max 2000 mg/day
All doses should be taken with meals to reduce GI side effects. - Harriet Lane Handbook, p. 1233

Adverse Effects

EffectNotes
GI symptomsMost common (~50%): nausea, bloating, diarrhea - dose-related, reduce by slow titration
Lactic acidosisRare but potentially fatal; risk elevated in renal impairment, hypoxia, hepatic disease
Vitamin B12 deficiencyLong-term use; monitor B12 annually; may worsen neuropathy

Contraindications & Precautions

  • eGFR < 30 mL/min/1.73 m²: Contraindicated (risk of lactic acidosis due to renal accumulation)
  • eGFR 30-45: Use with caution; reduce dose
  • Hepatic impairment: Contraindicated (impaired lactate clearance)
  • Iodinated contrast media: Hold metformin before/during procedures; restart 48 hours after if renal function is stable
  • CHF, metabolic acidosis, excessive alcohol use: Avoid
  • Surgical procedures: Temporarily hold
Drug interactions: Cimetidine, furosemide, nifedipine (OCT2/MATE inhibitors) can raise metformin levels. - Harriet Lane Handbook, p. 1234

Off-Label / Extended Uses

  • Polycystic ovary syndrome (PCOS): Improves insulin resistance, restores ovulation
  • Prediabetes / metabolic syndrome: Delays progression to T2DM
  • Gestational diabetes: Used in some guidelines (though insulin remains standard in many regions)
  • Clozapine-associated metabolic syndrome: Used to mitigate weight gain and insulin resistance
  • Anti-aging / longevity research: Active area of investigation (TAME trial)

Monitoring

  • Serum creatinine / eGFR: baseline and annually (or more often if at-risk)
  • HbA1c: every 3-6 months until stable, then every 6-12 months
  • Vitamin B12: baseline and every 1-2 years with long-term use
  • Fasting blood glucose

Recent Evidence (2024-2026)

Three recent systematic reviews highlight emerging aspects of metformin:
  • Exercise + metformin combination shows additive glycemic benefits in people with abnormal glycemic control (PMID: 39242178, Br J Sports Med, Dec 2024)
  • Dementia risk: A 2024 network meta-analysis found metformin may be associated with reduced dementia risk among antidiabetic agents (PMID: 39716328, Alzheimer's Res Ther)
  • Cardioprotective agents and dementia: A 2025 JAMA Neurology meta-analysis further evaluates metformin among cardioprotective agents for dementia risk reduction (PMID: 40193122)
Bottom line: Metformin remains the cornerstone of T2DM pharmacotherapy - effective, safe, affordable, and cardiometabolically beneficial. Its role may expand as evidence accumulates in aging, cancer prevention, and neurodegeneration.
This is a shared conversation. Sign in to Orris to start your own chat.